Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Idorsia Plans Daridorexant Programme in Autism After Paediatric Insomnia Findings – Idorsia

Written by | 17 Nov 2026 | Healthcare Practice

Idorsia Ltd announced that it is advancing a new development program to investigate daridorexant in autism spectrum disorder (ASD). The company is working on a dedicated formulation in parallel to discussions with global health authorities about the development program design in ASD, including the doses to be investigated.

Further details will be shared in H1 2027.

“We are intrigued by the observation from our clinical research that has opened an entirely new scientific avenue for daridorexant and Idorsia. The opportunity to investigate a potential new treatment approach for a condition where treatment options remain extremely limited gives this program particular significance. In addition to its potential impact for people living with ASD and their families, this opportunity demonstrates the value of combining rigorous analysis of our data with deep scientific understanding to uncover important new opportunities for patients and create long-term value for the company.” – Roland Wandeler, Chief Executive Officer.

The decision is based on findings from Idorsia’s randomized, placebo-controlled Phase 2 study of daridorexant in 165 children and adolescents with insomnia disorder, recently presented at Sleep Europe 2026 (Press release). The study evaluated objectively measured total sleep time after one dose of daridorexant 10, 25, and 50 mg. More than half of participants had diagnosed or subthreshold neurodevelopmental disorder, including ASD or attention-deficit/hyperactivity disorder (ADHD).

Autism spectrum disorder (ASD) is a lifelong neurodevelopmental disorder characterized by persistent impairments in social communication and interaction and by restricted or repetitive behaviors, interests, or activities. Support needs vary widely, with some people requiring lifelong care. ASD affects an estimated 61.8 million people worldwide. In the United States alone, it affects around 1 in 31 eight-year-old children.

“Every child with autism spectrum disorder is different, but for many, difficulties with communication, social interaction, and everyday functioning can shape almost every part of childhood and continue throughout life. Families often carry that burden alongside them, providing extraordinary levels of practical and emotional support while searching for therapeutical interventions that remain extremely limited. With no approved pharmacological treatment addressing the core features of ASD, investigating a new treatment approach offers much-needed hope for children, their caregivers and families, and the clinicians who care for them.” – Professor Carmen Schröder MD, PhD, Department of Child and Adolescent Psychiatry, Strasbourg University Hospitals, and member of Idorsia’s Autism Advisory Board.

Daridorexant had a distinct positive impact on affect and behavior, cognition, and daily activities for children with ASD.

At the Society for Developmental and Behavioral Pediatrics Annual Meeting, Idorsia presented an analysis of data from the participants with ASD or subthreshold ASD randomized in its dose-relationship study of daridorexant in children with insomnia disorder.

A single dose of daridorexant 50 mg, the highest recommended dose in adults, consistently improved the sleep parameters, including objective total sleep time in participants with ASD, ADHD, or no neurodevelopmental disorder.

The PROMIS Pediatric Sleep-Related Impairment questionnaire was used to assess the impact of sleep-related problems on daytime functioning. After only two weeks of treatment with daridorexant 50 mg, participants with ASD showed a distinct, consistent, and differentiated exploratory pattern of improvement across multiple facets of functioning compared to the overall population. The magnitude of impact was particularly noticeable on affect and behavior, cognition, and daily activities, facets highly relevant in ASD.

The consistent effect on sleep parameters across all participant subpopulations contrasting with the distinct exploratory pattern in participants with ASD on functioning may suggest that the observed effect is not solely mediated by an improvement in sleep but could extend to a treatment effect on autism spectrum disorder itself.

“The initial findings on improved sleep were already exciting for clinicians caring for children with insomnia, a highly underserved population. To then see a signal emerge early on in children with ASD, beyond insomnia, is even more powerful. The findings suggest that daridorexant could open a new avenue for patients with ASD. These findings now deserve prospective evaluation in a dedicated clinical program to determine whether the signal can be confirmed and translated into a meaningful benefit for children with ASD and their families.” – Professor Emerita Judith Owens, MD, MPH, Department of Neurology, Harvard Medical School.

A solid scientific rationale for the role of the orexin system in ASD

Following the unexpected clinical findings, further investigation revealed a biological rationale for orexin receptor antagonism in ASD.

Firstly, daridorexant, the investigated drug, is a dual orexin receptor antagonist that equipotently blocks orexin signaling through both the OX1 and OX2 receptors. Both receptors may be implicated in several functions including social interaction, behavioral flexibility, attention, motivation, stress response, and emotional regulation, several of which are affected in autism spectrum disorder.

Internal data analysis suggests a gene expression signature in autistic brain tissue that may indicate increased orexin signaling. Published findings reporting altered orexin levels in children with ASD provide additional external support for investigating the pathway.

“The distinct response observed in children and adolescents with ASD was unexpected. Together with our in-house findings suggesting high orexin signature in autism, and a growing understanding of how the OX1 and OX2 pathways may influence functions commonly affected in ASD, these observations provide a compelling scientific hypothesis for prospective evaluation. As an equipotent dual orexin receptor antagonist, daridorexant is particularly well suited. As a pediatrician, I personally find this new avenue of research both compelling and exciting.” – Martine Clozel, MD, Chief Scientific Officer and Head of Research.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.